BioLineRx Ltd (BLRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
69
About the Report
About the Report
Summary
BioLineRx Ltd (BioLineRx) is a clinical stage biopharmaceutical company that focuses on the identification, in-licensing, and development of products to address unmet medical needs. The company focuses mainly on cancer and immunology. Its's product pipeline includes BL-8040, a short peptide for multiple cancer and hematological indications; BL-5010, a novel medical device for non-surgical removal of skin lesions; and AGI-134 a synthetic alpha-gal immunotherapy for solid tumors. BioLineRx's pipeline also comprises BL-1230 and BL-9020 in preclinical development. The company in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel. BioLineRx is headquartered in Modi'in, Israel.
BioLineRx Ltd (BLRX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
BioLineRx Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioLineRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 10
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Agalimmune Raises USD2 Million in Venture Financing 13
Agalimmune Raises Funds Through Venture Financing Round 14
Private Equity 15
BVF Partners to Invest Additional USD9.6 Million in BioLineRx 15
Partnerships 16
BioLineRx Enters into Agreement with Genentech 16
BioLineRx Forms Joint Venture with I-Bridge Capital 17
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 18
BioLineRx Expands Licensing Agreement with Merck 19
BioLineRx Enters into Agreement with Novartis Pharma 20
BioLineRx Enters Into Co-Development Agreement With JHL Biotech 21
Licensing Agreements 23
BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 23
BGN Tech Enters into Licensing Agreement with BioLineRx 24
BioLineRx Enters into Licensing Agreement with Hadassah Medical Organization 25
Agalimmune Enters into Licensing Agreement with KODE Biotech 26
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27
BioLineRx Enters Into Licensing Agreement with Jiangsu Chia-tai Tianqing Pharma For BL-8030 28
BioLineRx Enters Into Licensing Agreement With Biokine Therapeutics For BL-8040 29
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 31
BioLineRx Enters into Licensing Agreement for Treatment of Neuropathic Pain 32
University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 33
BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 34
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020 36
Equity Offering 37
BioLineRx to Raise up to USD30 Million in Public Offering of American Depositary Shares 37
BioLineRx Raises USD28.8 Million Public Offering of American Depositary Shares 38
BioLineRx Raises USD28.8 Million in Public Offering of American Depositary Shares 40
BioLineRx to Raise up to USD20 Million in Private Placement of American Depositary Shares 42
BioLineRx Completes Public Offering Of American Depositary Shares For USD 24.2 Million 43
BioLineRx Completes Private Placement Of American Depositary Shares For USD 8 Million 44
BioLineRx Completes Private Placement Of American Depositary Shares For USD 15 Million 45
Acquisition 46
BioLineRx Acquires Agalimmune 46
BioLineRx Ltd-Key Competitors 47
BioLineRx Ltd-Key Employees 48
BioLineRx Ltd-Locations And Subsidiaries 49
Head Office 49
Other Locations & Subsidiaries 49
Joint Venture 49
Recent Developments 50
Financial Announcements 50
Aug 13, 2018: BioLineRx reports second quarter 2018 financial results 50
May 22, 2018: BioLineRx Reports First Quarter 2018 Financial Results 52
Mar 06, 2018: BioLineRx Reports Year End 2017 Financial Results 54
Nov 21, 2017: BioLineRx Reports Third Quarter 2017 Financial Results 57
Aug 08, 2017: BioLineRx announces Q2 2017 Financial Results 59
May 25, 2017: BioLineRx Reports First Quarter 2017 Financial Results 61
Mar 23, 2017: BioLineRx Reports Year End 2016 Financial Results 63
Clinical Trials 65
May 03, 2017: BioLineRx to Initiate Phase 3 Study with BL-8040 as Novel Stem Cell Mobilization Treatment Following Successful Meeting with FDA 65
Mar 20, 2017: BioLineRx Provides Update on Phase 2 Open-Label Study for BL-8040 as Novel Stem Cell Mobilization Treatment 66
Jan 17, 2017: BioLineRx Announces Initiation of Immuno-Oncology Phase 2 Study to Investigate Combination of BL-8040 and KEYTRUDA for Pancreatic Cancer 67
Appendix 68
Methodology 68
About GlobalData 68
Contact Us 68
Disclaimer 68
List of Figure
List of Figures
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
BioLineRx Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
BioLineRx Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
BioLineRx Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
BioLineRx Ltd, Medical Devices Deals, 2012 to YTD 2018 10
BioLineRx Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Agalimmune Raises USD2 Million in Venture Financing 13
Agalimmune Raises Funds Through Venture Financing Round 14
BVF Partners to Invest Additional USD9.6 Million in BioLineRx 15
BioLineRx Enters into Agreement with Genentech 16
BioLineRx Forms Joint Venture with I-Bridge Capital 17
BioLineRx to Enter into Agreement with University of Texas MD Anderson Cancer Center 18
BioLineRx Expands Licensing Agreement with Merck 19
BioLineRx Enters into Agreement with Novartis Pharma 20
BioLineRx Enters Into Co-Development Agreement With JHL Biotech 21
BioLineRx Enters into Licensing Agreement with Yissum Research Development Company of the Hebrew University of Jerusalem 23
BGN Tech Enters into Licensing Agreement with BioLineRx 24
BioLineRx Enters into Licensing Agreement with Hadassah Medical Organization 25
Agalimmune Enters into Licensing Agreement with KODE Biotech 26
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 27
BioLineRx Enters Into Licensing Agreement with Jiangsu Chia-tai Tianqing Pharma For BL-8030 28
BioLineRx Enters Into Licensing Agreement With Biokine Therapeutics For BL-8040 29
BioLineRx Enters Into Licensing Agreement With Genoscience Pharma And RFS Pharma For BL-8030 31
BioLineRx Enters into Licensing Agreement for Treatment of Neuropathic Pain 32
University of Massachusetts Medical School Enters Into Licensing Agreement With Agalimmune For Alphaject 33
BioLineRx Enters Into Licensing Agreement With Yissum, B.G. Negev Technologies And Hadasit Medical 34
BioLineRx Enters Into Licensing Agreement With Genoscience For BL-8020 36
BioLineRx to Raise up to USD30 Million in Public Offering of American Depositary Shares 37
BioLineRx Raises USD28.8 Million Public Offering of American Depositary Shares 38
BioLineRx Raises USD28.8 Million in Public Offering of American Depositary Shares 40
BioLineRx to Raise up to USD20 Million in Private Placement of American Depositary Shares 42
BioLineRx Completes Public Offering Of American Depositary Shares For USD 24.2 Million 43
BioLineRx Completes Private Placement Of American Depositary Shares For USD 8 Million 44
BioLineRx Completes Private Placement Of American Depositary Shares For USD 15 Million 45
BioLineRx Acquires Agalimmune 46
BioLineRx Ltd, Key Competitors 47
BioLineRx Ltd, Key Employees 48
BioLineRx Ltd, Subsidiaries 49
BioLineRx Ltd, Joint Venture 49
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.